Debt-to-equity of KIORA PHARMACEUTICALS INC from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
KIORA PHARMACEUTICALS INC quarterly Debt-to-equity in % history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • KIORA PHARMACEUTICALS INC Debt-to-equity for the quarter ending 30 Sep 2025 was 41%, a 36% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

KIORA PHARMACEUTICALS INC Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 41% +11% +36% 30 Sep 2025
Q2 2025 39% +1% +3.9% 30 Jun 2025
Q1 2025 33% -13% -29% 31 Mar 2025
Q4 2024 28% -46% -62% 31 Dec 2024
Q3 2024 30% -34% -53% 30 Sep 2024
Q2 2024 37% -22% -37% 30 Jun 2024
Q1 2024 46% -21% -31% 31 Mar 2024
Q4 2023 74% +8% +12% 31 Dec 2023
Q3 2023 64% +7% +12% 30 Sep 2023
Q2 2023 59% +11% +22% 30 Jun 2023
Q1 2023 67% +21% +46% 31 Mar 2023
Q4 2022 66% +20% +45% 31 Dec 2022
Q3 2022 57% +8% +17% 30 Sep 2022
Q2 2022 49% -5% -9.8% 30 Jun 2022
Q1 2022 46% -4% -8.7% 31 Mar 2022
Q4 2021 45% 0% -0.42% 31 Dec 2021
Q3 2021 49% +6% +13% 30 Sep 2021
Q2 2021 54% +8% +18% 30 Jun 2021
Q1 2021 51% +9% +20% 31 Mar 2021
Q4 2020 45% +6% +15% 31 Dec 2020
Q3 2020 43% +1% +1.9% 30 Sep 2020
Q2 2020 46% +5% +12% 30 Jun 2020
Q1 2020 42% -1% -2.6% 31 Mar 2020
Q4 2019 39% -18% -31% 31 Dec 2019
Q3 2019 42% -76% -64% 30 Sep 2019
Q2 2019 41% -204% -83% 30 Jun 2019
Q1 2019 43% -553% -93% 31 Mar 2019
Q4 2018 57% -2632% -98% 31 Dec 2018
Q3 2018 119% -1269% -91% 30 Sep 2018
Q2 2018 245% -455% -65% 30 Jun 2018
Q1 2018 596% +148% +33% 31 Mar 2018
Q4 2017 2690% 31 Dec 2017
Q3 2017 1387% 30 Sep 2017
Q2 2017 699% 30 Jun 2017
Q1 2017 448% 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.